Antibiotic therapy and prophylaxis of infective endocarditis – A SPILF-AEPEI position statement on the ESC 2023 guidelines
Vincent Le Moing, É. Bonnet, Vincent Cattoir, Catherine Chirouze, Laurène Deconinck, Xavier Duval, Bruno Hoen, Nahéma Issa, R. Lecomte, Pierre Tattevin, Asmaa Tazi, François Vandenesch, C. Strady
Abstract
• The AEPEI) and the SPILF) are providing a consensus statement on the antibiotic treatment and prophylaxis of infective endocarditis (IE) based on the ESC guidelines published in 2023. • Antibiotic prophylaxis in patients at high risk of IE should be prescribed only before at-risk oro-dental situations. • In streptococcal IE, choice of β-lactam should be based on the Minimal Inhibitory Concentration (MIC). • In staphylococcal prosthetic valve IE, two antibiotics should be used, combining an antistaphylococcal agent (β-lactam or daptomycin) and gentamicin replaced by rifampicin after sterilization of blood cultures. • Switch to oral antibiotic therapy may be implemented for patients with streptococcal IE meeting the relevant stability criteria after at least 10 days of effective IV antibiotic therapy and at least 7 days after valve surgery.